Conventional medicine often puts patients in a difficult spot. Fibromyalgia patients are told,”your disease is chronic and incurable and we really don’t understand it but take this expensive medication that may also give you side effects. It may make you feel better and it may not.” Ironically, research shows that a nutritional supplement, CoQ10, may be more effective…
At least that’s what my doctor told me. And the chemotherapy managed my cancer for about a year an a half leaving me with serious side effects before I became end-stage. That’s when I decided to take responsibility for my own health. I have been taking Coq10 for years to help manage my chemo-induced heart damage, my chemo-induced nerve damage and I have learned that Coq10 may even be helping me stay cancer-free.
The studies linked and excerpted below report that “After Coq10 treatment, the patient reported a significant improvement of clinical symptoms…”
Coq10 has been shown by evidence-based research to manage a host of health problems. If you’ve never heard of Coq10, you may have read about ubiquinone or ubiquinol– the other names it goes by. The only difference between the two is the chemical form. According to Consumerlab.com, an independent testing service “optimal blood levels of Coq10 may improve heart function through improved ejection fraction, reverse statins side effects, may prevent migraine headaches and pre-eclampsia. CoQ10 supplementation may be useful in treating diseases including muscular dystrophy, AIDS, and hypertension.”
I supplement with Doctor’s Best High Absorption Coq10 w/ BioPerine because this supplement has been tested and approved by Consumerlab.com for purity and absorbability. 5% of your purchase will go to PeopleBeatingCancer. Thank you.
For more information about chronic disease management, scroll down the page, post a question or comment and I will reply ASAP.
“Low CoQ(10) levels have been detected in patients with Fibromyalgia (FM)…Patients with CoQ(10) deficiency showed a statistically significant reduction on symptoms after CoQ(10) treatment during 9 months (300 mg/day). Determination of deficiency and consequent supplementation in FM may result in clinical improvement…”
“Fibromyalgia (FM) is a chronic pain syndrome with unknown etiology. Recent studies have shown evidence demonstrating that mitochondrial dysfunction and oxidative stress may have a role in the pathophysiology of FM. Coenzyme Q10 (CoQ10) is an essential electron carrier in the mitochondrial respiratory chain and a strong antioxidant. Low CoQ10 levels have been detected in patients with FM, and a significant decrease of clinical symptoms has been reported after oral CoQ10 supplementation…
After CoQ10 treatment, the patient reported a significant improvement of clinical symptoms… Our results suggest that CoQ10 could be an alternative therapeutic approach for FM.”
“Fibromyalgia (FM) is a complex disorder that affects up to 5% of the general population worldwide. Its pathophysiological mechanisms are difficult to identify and current drug therapies demonstrate limited effectiveness. Both mitochondrial dysfunction and coenzyme Q10 (CoQ10) deficiency have been implicated in FM pathophysiology.
We have investigated the effect of CoQ10 supplementation. We carried out a randomized, double-blind, placebo-controlled trial to evaluate clinical and gene expression effects of forty days of CoQ10 supplementation (300 mg/day) on 20 FM patients.
An important clinical improvement was evident after CoQ10 versus placebo treatment showing a reduction of FIQ (p<0.001), and a most prominent reduction in pain (p<0.001), fatigue, and morning tiredness (p<0.01) subscales from FIQ.
Furthermore, we observed an important reduction in the pain visual scale (p<0.01) and a reduction in tender points (p<0.01), including recovery of inflammation, antioxidant enzymes, mitochondrial biogenesis, and AMPK gene expression levels, associated with phosphorylation of the AMPK activity.
These results lead to the hypothesis that CoQ10 have a potential therapeutic effect in FM, and indicate new potential molecular targets for the therapy of this disease. AMPK could be implicated in the pathophysiology of FM.”